Evidence for a causal association for HPV in head and neck cancers

Sudhoff, Holger; Schwarze, Hartmut; Winder, David M.; Steinstraesser, Lars; Görner, Martin; Stanley, Margaret; Goon, Peter

doi:10.1007/s00405-011-1714-8

Cited by 50 publications

(26 citation statements)

References 66 publications

(70 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is demonstrated that HPV infection is causally related to head and neck cancers (Kreimer et al, 2005;Strati et al, 2006;Gillison et al, 2012b;Jung et al, 2010). A strong association between HPV16 and oropharyngeal cancer has been demonstrated in frequent case-control studies (Kreimer et al, 2005;Sudhoff et al, 2011). Moreover, a small fraction of head and neck cancers may be caused by further HPV types such as HPV18, 31, 33, 35 (Gillison et al, 2012a).…”

Section: Discussionmentioning

confidence: 99%

Human Papillomavirus Burden in Different Cancers in Iran: a Systematic Assessment

Jalilvand¹,

Shoja²,

Hamkar³

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Certain types of human papillomaviruses (HPVs) are undoubtedly involved in genesis of human malignancies. HPV plays an etiological role in cervical cancer, but also in many vaginal, vulvar, anal and penile cancers, as well as head and neck cancers. In addition, a number of non-malignant diseases such as genital warts and recurrent respiratory papillomatosis are attributable to HPV. Moreover, HPV forms have detected in several other cancers including esophageal squamous cell carcinoma, lung, prostate, ovarian, breast, skin, colorectal and urinary tract cancers, but associations with etiology in these cases is controversial. The aim of this systematic assessment was to estimate the prevalence of HPV infection and HPV types in HPV-associated cancers, HPV-related non-malignant diseases and in cancers that may be associated with HPV in Iran. The present investiagtion covered 61 studies on a variety of cancers in Iranian populations. HPV prevalence was 77.5 % and 32.4% in cervical cancer and head and neck cancers, respectively. HPV was detected in 23.1%, 22.2%, 10.4%, 30.9%, 14% and 25.2% of esophageal squamous cell, lung, prostate, urinary tract cancers, breast and skin cancers, respectively. HPV16 and 18 were the most frequent HPV types in all cancers. The findings of present study imply that current HPV vaccines for cervical cancer may decrease the burden of other cancers if they are really related to HPV.

show abstract

Section: Discussionmentioning

confidence: 99%

Human Papillomavirus Burden in Different Cancers in Iran: a Systematic Assessment

Jalilvand¹,

Shoja²,

Hamkar³

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Human PVs (HPVs) cause 5% of all human solid cancers, including virtually all cervical cancers, 25% of head and neck cancers, and some anal and lung cancers (National Cancer Institute home page; Rautava and Syrjänen, 2012;Stanley, 2012;Sudhoff et al, 2011;Joh et al, 2010;Psyrri and DiMaio, 2008;Desai et al, 2009;Jenson et al, 2001;Saman, 2012;Gillison et al, 2012;Campo, 2002). PVs are highly species-specific, non-enveloped small DNA viruses whose replication is largely restricted to individual anatomical sites (Howley and Lowy, 2007).…”

Section: Introductionmentioning

confidence: 99%

MmuPV1 infection and tumor development of T cell-deficient mice is prevented by passively transferred hyperimmune sera from normal congenic mice immunized with MmuPV1 virus-like particles (VLPs)

Joh

Ghim

Chilton

et al. 2016

Experimental and Molecular Pathology

View full text Add to dashboard Cite

“…The human papillomavirus (HPV) is the aetiological cause of several benign and malignant tumors 1, 2, 3. Although recurrent respiratory papillomatosis (RRP) is a rare disease, there is severe morbidity and occasional mortality.…”

Section: Introductionmentioning

confidence: 99%

Recurrent respiratory papillomatosis (RRP)–time for a reckoning?

Goon

Scholtz²,

Sudhoff³

2017

Laryngoscope Investig Oto

View full text Add to dashboard Cite

ObjectivesRecurrent respiratory papillomatosis (RRP) is a rare disease, but one with severe morbidity and occasional mortality. The aetiological agent is human papillomavirus (HPV), and HPV types 6 and 11 account for over 90% of all cases. In the active phase of the disease, patients require multiple hospital admissions for surgical removal or ablation of these benign tumors, which are likely to obstruct the airways if left unchecked. Long‐term sequelae include scarring of the vocal cords, change in voice timbre, or even muteness if a tracheostomy is required. The aim of this study was to determine if adjuvant vaccination with the quadrivalent HPV L1 vaccine (Gardasil™) would decrease numbers of surgical treatments post‐vaccination.MethodsA prospective pilot study following a cohort of 12 RRP patients, all of whom gave fully informed consent to participate. All patients had their papillomas typed and if they were found to have types 6 or 11, were vaccinated at the time of first surgical treatment in the hospital, according to the manufacturer's protocols. Patients were followed up closely with 3 or 6 month follow‐up visits. Standard surgical treatments were given and were not affected by whether they participated in the study.ResultsWe found a >7‐fold decrease in the incidence rates of papillomatosis requiring surgical intervention from the pre‐vaccination period (47.44/1000 patient‐months) compared to the post‐vaccination period (6.71/1000 patient‐months).DiscussionSurgical treatments for RRP are robust markers for papillomata which require treatment because of the dangers of obstruction of the airway. Despite the small size of this cohort (due to the rarity of this disease), the data suggests that adjuvant use of quadrivalent HPV L1 vaccine imparts significant benefit to this group of patients. A large multi‐center randomized placebo controlled trial is required to definitively establish whether this hypothesis is true and can become the new standard of therapy.Level of Evidence3b

show abstract

Evidence for a causal association for HPV in head and neck cancers

Cited by 50 publications

References 66 publications

Human Papillomavirus Burden in Different Cancers in Iran: a Systematic Assessment

Human Papillomavirus Burden in Different Cancers in Iran: a Systematic Assessment

MmuPV1 infection and tumor development of T cell-deficient mice is prevented by passively transferred hyperimmune sera from normal congenic mice immunized with MmuPV1 virus-like particles (VLPs)

Recurrent respiratory papillomatosis (RRP)–time for a reckoning?

Contact Info

Product

Resources

About